Retatrutide

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.In addition to weight loss, retatrutide showed promise in improving glycemic control. Prediabetes reverted to normoglycemia in 72% of participants. The drug also showed a positive impact on cardiovascular health markers, including significant reductions in systolic and diastolic blood pressure and an improved lipid profile.Mild-to-moderate side effects and drug mechanism
The most common adverse events were mild-to-moderate gastrointestinal events, primarily during the dose escalation period. Researchers attribute the drug’s efficacy to its agonistic effects on the glucagon, GIP and GLP-1 receptors, indicating potential roles these receptors play in achieving the therapeutic effects of retatrutide.